User:SDZeroBot/NPP sorting/STEM/Chemistry: Difference between revisions

Revision as of 01:50, 9 August 2025

Latest revision as of 13:50, 1 September 2025

(46 intermediate revisions by the same user not shown)

Line 1:

{{User:SDZeroBot/NPP sorting/header|count=1116|date=91 AugustSeptember 2025|ts=0113:50, 91 AugustSeptember 2025 (UTC)}}

{| class="wikitable sortable"

Line 10:

! scope="col" style="width: 4em;" | Notes

|-

| 2024-1101-1011

| [[Qing-YunSamarium(III) Chenantimonide]] <small>(ChineseChemical chemist (1929-2023)compound)</small>

| Samarium antimonide is a binary inorganic compound of [[samarium]] and [[antimony]] with the formula SmSb. It forms crystals.

| Qing-Yun Chen ({{zh|s=陈庆云|p=Chén Qìngyún}}; 25 January 1929 – 2 March 2023) was a Chinese [[organic chemist]] and member of the [[Chinese Academy of Sciences]], specializing in the field of organic fluorine chemistry.

| Stub

| data-sort-value=556622454 | [[Special:Contribs/Noxoug1Praseodymium-141|Noxoug1Praseodymium-141]] (556622454)

|

|-

| 20222024-01-0618

| [[Porous polymer]]

| Porous polymers are a class of [[porous media]] materials in which [[monomer]]s form [[2D polymer|2D]] and [[3D polymers]] containing angstrom- to nanometer-scale pores formed by the arrangement of the monomers. They may be either crystalline or amorphous. Subclasses include [[covalent organic framework]]s (COFs), [[hydrogen-bonded organic framework]]s (HOFs), [[metal-organic framework]]s (MOFs), and [[porous organic polymer]]s (POPs).

| Start

| data-sort-value=82888895 | [[Special:Contribs/Tokisaki KurumiMichael7604|Tokisaki KurumiMichael7604]] (82888895)

|

|-

| 2024-1201-1722

| [[DazadrolPraseodymium monoselenide]] <small>(Dazadrol is anChemical antidepressantcompound)</small>

| Praseodymium monoselenide is a compound with the chemical formula PrSe. It forms crystals.

| Dazadrol is a synthetic [[antidepressant]] developed by [[Schering-Plough|Schering Corp]] in the late 1960s. It acts primarily as a [[noradrenaline reuptake inhibitor]], increasing concentrations of noradrenaline in the [[synaptic cleft]], which is believed to underlie its antidepressant effects.

| Stub

| data-sort-value=26022454 | [[Special:Contribs/Mo18ekulaPraseodymium-141|Mo18ekulaPraseodymium-141]] (26022454)

|

|-

| 20252024-0501-1926

| [[TransitionIron(III) metal catalytic asymmetric dearomatization reactionsselenite]] <small>(Category of organic chemicalChemical reactionscompound)</small>

| Iron(III) selenite is an inorganic compound with the chemical formula Fe₂(SeO₃)₃. It exists anhydrous form and as various hydrates. The heptahydrate is produced by the reaction of [[ferric chloride]] and [[selenous acid]] (or [[sodium selenite]]) at a pH of 1.05.

| Catalyzed asymmetric dearomatization reactions (CADA reactions) are a category of asymmetric [[Dearomatization reaction|dearomatization reactions]] that catalytically transform [[Aromatic compound|aromatic compounds]] into enantioenriched [[Polycyclic compound|polycycles]] and [[Heterocyclic compound|heterocyclic]] skeletons. The term was coined in 2012 by You et al.

| Start

| data-sort-value="A0"|FA

| data-sort-value=3822454 | [[Special:Contribs/PchemExtraordinairePraseodymium-141|PchemExtraordinairePraseodymium-141]] (3822454)

|

|-

| 2025-05-23

| [[Cefepime/sulbactam]] <small>(Combination antibiotic consisting of the IV generation)</small>

| Cefepime/sulbactam is a 1:1 [[fixed-dose combination]] of [[cefepime]] (a fourth-generation cephalosporin) and [[sulbactam]] (a β-lactamase inhibitor). The combination exerts a bactericidal effect by disrupting bacterial cell wall synthesis through transpeptidase inhibition, thereby impairing peptidoglycan cross-linking.

| C

| data-sort-value=37 | [[Special:Contribs/Хокус Покус 333|Хокус Покус 333]] (37)

|

|-

| 20252024-0501-3110

| [[NitazenesFudosteine]] <small>(ClassChemical of drugscompound)</small>

| [[Musahaqah]]

| Fudosteine (Cleanal) is a [[mucolytic agent]]. In Japan, it is approved for the treatment of [[bronchial asthma]], [[chronic bronchitis]], [[pulmonary emphysema]], [[bronchiectasis]], [[pulmonary tuberculosis]], [[pneumoconiosis]], atypical [[mycobacterial disease]], and [[diffuse panbronchiolitis]].

| Musaheqeh ({{Langx|ar|مساحقه}}) is a legal and religious term. In [[Fiqh|Islamic jurisprudence]] ([[fiqh]]) and under the [[Islamic Penal Code of Iran]], musaheqeh refers to a situation in which an adult, mentally competent, and consenting [[woman]] brings her [[Sex organ|genitalia]] into contact with the genitalia of another woman.

| Stub

| data-sort-value=24435014 | [[Special:Contribs/JesusisGreat7Innerstream|JesusisGreat7Innerstream]] (24435014)

|

|-

Line 50:

| Stub

| data-sort-value=646 | [[Special:Contribs/BaeyerDrewson|BaeyerDrewson]] (646)

|

|-

| 2025-05-22

| [[225Ac-PSMA-R2]] <small>(Investigational radiopharmaceutical)</small>

| 225Ac-PSMA-R2 is an investigational [[radiopharmaceutical]] developed by [[Novartis]] for the treatment of metastatic hormone-sensitive prostate cancer (mHSPC) and [[metastatic castration-resistant prostate cancer]] (mCRPC). It is a [[targeted alpha therapy]] (TAT) combining [[actinium-225]] (225Ac), an alpha-emitting [[radionuclide]], with PSMA-R2, a small-molecule [[ligand]] targeting [[prostate-specific membrane antigen]] (PSMA), a protein overexpressed in prostate cancer cells.

| C

| data-sort-value=5566 | [[Special:Contribs/Noxoug1|Noxoug1]] (5566)

|

|-

Line 63 ⟶ 56:

| ¹⁷⁷Lu-NNS309 is an investigational radiopharmaceutical compound currently under development by Novartis Pharmaceuticals for the treatment of various [[Neoplasm|solid tumors]]. The compound is being evaluated in Phase I clinical trials for patients with pancreatic, lung, breast, and colorectal cancers.

| C

| data-sort-value=55665704 | [[Special:Contribs/Noxoug1|Noxoug1]] (55665704)

|

|-

| 2022-01-06

| [[Nitazenes]] <small>(Class of drugs)</small>

| Nitazenes are a chemically defined class of substances derived from the [[Parent structure|parent compound]] [[nitazene]]. Nitazenes were developed in the second half of the 1950s by the Swiss [[Novartis|Ciba AG]] as [[analgesic|pain-relieving agents]]. They are important as [[central nervous system|centrally]] active, selective [[μ-opioid receptor]] [[agonist]]s.

| C

| data-sort-value=38113 | [[Special:Contribs/Idoghor Melody|Idoghor Melody]] (38113)

|

|-

Line 77 ⟶ 63:

| OpRegen (also known as RG6501) is an investigational allogeneic cell therapy developed by Lineage Cell Therapeutics for the treatment of geographic atrophy (GA) secondary to dry age-related macular degeneration (AMD). The therapy consists of human retinal pigment epithelial (RPE) cells administered via subretinal injection as a single treatment.

| C

| data-sort-value=55665704 | [[Special:Contribs/Noxoug1|Noxoug1]] (55665704)

|

|-

| 2025-0501-2219

| [[Fluorescence upconversion]] <small>(Ultrafast laser spectroscopic technique)</small>

| Fluorescence upconversion (FU) is an [[Ultrafast laser spectroscopy|ultrafast laser spectroscopic]] technique. It is a variant of [[sum-frequency generation]] (of which the [[second-harmonic generation]] (SHG) is a special case) but applied to the detection of the incoherent [[fluorescence]]. It is therefore closely related to the [[Optical Kerr Gating]] (OKG) technique.

| C

| data-sort-value=38113104 | [[Special:Contribs/Idoghor MelodyOzzwah|Idoghor MelodyOzzwah]] (38113104)

|

|-

| 2025-08-18

| [[Jens Bruun de Neergaard]] <small>(Danish judge and landowner)</small>

| Jens Bruun de Neergaard (14 June 1742 – 22 April 1788) was a [[Denmark|Danish]] judge and landowner. He owned [[Svenstrup (manor house)|Svenstrup Manor]], at [[Borup, Køge|Broup]], [[Køge Municipality]], whouse present main building he constructed in the 1780s. On 31 May 1780, alongside his younger brother, Johan Thomas de Neergaard (1745–1806), he was ennobled by [[letters patent]].

| Start

| data-sort-value=88199 | [[Special:Contribs/Ramblersen2|Ramblersen2]] (88199)

|

|-

| 2025-08-04

| [[CinnabarinicHellenic acidChampionship (Tennis)]] <small>(ChemicalTennis compoundtournament)</small>

| The Hellenic Championship is an [[ATP 250 tournaments|ATP 250 tournament]] held in [[Athens]], [[Greece]]. The event is played on indoor [[hardcourt]] at the [[OAKA Basketball Arena]], a multi-purpose venue that was used for the [[2004 Summer Olympics]]. It replaces the [[Belgrade Open]] on the calendar and it is scheduled to debut in November 2025.

| Cinnabarinic acid is a [[metabolite]] formed through the oxidative processing of [[tryptophan]]. It is an endogenous metabolite of the [[kynurenine pathway]] of [[tryptophan]] catabolism, formed by oxidative dimerization of two molecules of [[3-hydroxyanthranilic acid]]. It functions both as a partial agonist at type 4 [[metabotropic glutamate receptors]] (mGlu₄) and as a ligand for the [[aryl hydrocarbon receptor]] (AhR), with implications for [[neuroprotection]] and [[immunomodulation]].

| Stub

| data-sort-value=374026 | [[Special:Contribs/ХокусHaddad ПокусMaia 333fan|ХокусHaddad ПокусMaia 333fan]] (374026)

|

|-

| 2025-08-13

| [[Structural Dynamics Response Assay]] <small>(Biochemical analysis procedure)</small>

| The structural dynamics response (SDR) assay is a type of [[biophysical]] test used to measure [[ligand binding]] to a target [[protein]]. The assay is configured as a simple mix and read format that can be conducted in very low volumes, therefore suitable for [[drug discovery]] applications such as [[high throughput screening]] (HTS), or in the development of a drug candidate during [[medicinal chemistry]] optimization cycles.

| Start

| data-sort-value=37374 | [[Special:Contribs/FlarpenXHoffmacs|FlarpenXHoffmacs]] (37374)

|

|-

| 2025-06-16

| [[Sefaxersen]] <small>(Antisense oligonucleotide therapy under development)</small>

| Sefaxersen (also known as RO7434656, RG6299, ISIS-696844 and IONIS-FB-LRx) is an investigational [[antisense oligonucleotide]] (ASO) drug developed by [[Roche Holding AG]] in partnership with [[Ionis Pharmaceuticals]]. It targets [[complement factor B]] (CFB) to treat [[complement system]]-mediated diseases, primarily [[IgA nephropathy]] (IgAN) and [[geographic atrophy]] (GA) secondary to [[age-related macular degeneration]].

| C

| data-sort-value=5704 | [[Special:Contribs/Noxoug1|Noxoug1]] (5704)

|

|-

| 2025-08-31

| [[Maurizio Cignitti]]

| Maurizio Cignitti (Rome, 24 July 1930 – Rome, 10 January 2017) was an Italian chemist and researcher, known for his work in theoretical chemistry, medicinal chemistry, and biologically relevant molecular interactions. He held prominent positions at the Istituto Superiore di Sanità (Italian National Institute of Health) and contributed to major international negotiations on ozone layer depletion and to the harmonization of European pharmacopeias.

| C

| data-sort-value=22 | [[Special:Contribs/Piman61|Piman61]] (22)

|

|-

| 2025-05-2304

| [[Erythrocyte-based drug delivery]] <small>(Drug delivery method)</small>

| Erythrocyte-based drug delivery systems (EBDDS) use [[red blood cells]], their membranes, or their components to release and deliver pharmaceutical agents throughout the body in a controlled manner. Because red blood cells circulate for long periods of time and are potentially non-[[immunogenic]], they are an attractive vector for [[drug delivery]] via the circulatory system.

| C

| data-sort-value=6 | [[Special:Contribs/DrugDelivery2025|DrugDelivery2025]] (6)

|

|-

| 2025-07-31

| [[Vatinoxan]] <small>(Pharmaceutical compound)</small>

| Vatinoxan, originally known as MK-467, is an [[Alpha-2_adrenergic_receptor#Antagonists|α₂-adrenergic receptor antagonist]] used in veterinary medicine alongside [[Alpha-2_adrenergic_receptor#Agonists|α₂-adrenergic receptor agonists]] to counteract [[vasoconstriction]] and [[hypertension]] while maintaining sedation. Vatinoxan does not cross the [[blood–brain barrier]] giving it a unique pharmacological profile compared to the other α₂-adrenergic receptor antagonists and distinct clinical application.

| C

| data-sort-value=499 | [[Special:Contribs/Sacristy|Sacristy]] (499)

|

|}

<span style="font-style: italic; font-size: 85%;">Last updated by [[User:SDZeroBot|SDZeroBot]] ^{''[[User:SD0001|operator]] / [[User talk:SD0001|talk]]''} at 0113:50, 91 AugustSeptember 2025 (UTC)</span>